BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to)
Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginall
Aclaris Therapeutics Inc (NASDAQ: ACRS) announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed
Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005) All six key secondary endpoints, including patient global impression,
Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and